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Material and Methods: This study reviewed cancer registry 
data of our hospital from 2004 to 2012 with following 
inclusion criteria: ESC were found at least 90 days after HNC 
in the same patient, and both were diagnosed with pathology 
of invasive cancer. Patients would be excluded with following 
criteria: ESC was an extension of HNC or vice versa, and no 
available information of treatment could be retrieved. 
Treatment was composed by combinations of radiotherapy, 
chemotherapy, and surgery depending on disease status and 
performance status of the patient. The primary end point 
was overall survival (OS), and the second endpoint was 
progression-free survival (PFS). 
 
Results: 77 patients were eligible. The median time from 
HNC to ESC was 32 months (4 – 147 months). Fifty-three 
patients (60%) were stage III/IV and 15 patients received best 
supportive care only after diagnosis of ESC. After excluding 
the BSC group, the 2-year OS were 34.9%. Fifteen patients 
were alive and one of them still had ESC. Thirty-five, 10, and 
2 patients died from ESC, treatment related complications, 
and other disease, respectively. Univariate analysis revealed 
that ECOG > 1, tube feeding, anemia, and no esophagectomy 
correlated with poor OS (p < 0.05). Multivariate analysis 
showed that lower hemoglobin level, habit of smoking, ECOG 
score = 2, and no esophagectomy were independent poor 
prognostic factors (p < 0.05). The 2-year PFS rate for all 
patients was 30.7%. In the univariate analysis, ECOG > 1, tube 
feeding, body weight loss > 5%, anemia, no esophagectomy, 
and ESCstage III/IV were significantly correlated with poor 
PFS (p < 0.05). In the multivariate analysis, anemia and no 
esophagectomy were independently correlated with tumor 
recurrence (p < 0.05). Treatment outcome of patients who 
received esophagectomy were similar to ESC patients without 
prior history of HNC. The 2-year OS and PFS were 63.9% and 
50.6%, respectively. Both were significantly higher than 
patients who did not receive esophagectomy (11.8% and 9.9%, 
p < 0.01). 
 
Conclusion: the treatment result of metachronous ESC after 
HNC varied with disease and patient status. If esophagectomy 
was possible, the treatment outcome was not inferior to 
esophageal cancer without prior head and neck cancer 
history. But the treatment outcome was poor in patients with 
unresectable disease or poor performance status. A screening 
program for metachronous ESC should be considered for high 
risk patients to detect resectable ESC and improve treatment 
outcome. 
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Purpose or Objective: Evaluate the salvage radiotherapy 
outcome in patients with supraclavicular lymph node 
metastases (SCLN) after esophagectomy. 
 
Material and Methods: A total of 117 patients with 
esophageal squamous cell carcinoma after initial 
esophagectomy (R0 resection) were retrospectively analyzed 
and they were diagnosed supraclavicular lymph node 
metastases during follow-up time. All patients were divided 
into salvage radiotherapy group (SR, n=89) and no salvage 
radiotherapy group (NSR, n=27). 
 
Results: The 1,3,5-year overall survival rates were 
81.6%、31.4%、8.6%, respectively. In all patients the 1,3-year 
survival time after SCLN metastasis (ASMS) rates were 
40.2%、14.5%, and the median ASMS time was 10 months. 
The 1, 3-year ASMS rates were 48.1%、18.9% in SR group and 
12.0%、0% in NSR group,respectively (P<0.001). In SR group, 
the 1, 3-year ASMS rates in the patients with combined 
radiochemotherapy and single radiotherapy were 62.6%, 
33.4% and 41.9%, 16.5% (P<0.001). In the subgroup analysis, 
in combining visceral metastases group (CVM), the 1,3-year 
ASMS rates were 35.5% , 0%, and 42.3%, 21.5% in no 
combining visceral metastases group (NCVM) (P = 0.004). The 
3-year ASMS rate with the patients in no combining 
mediastinal failure group (NCMF) (22.2%) was higher than 
those in combining mediastinal failure group (CMF) (7.0%) 
(p=0.041). According to the salvage radiation dose, the 1,3-
year ASMS rates were 56.5%, 23.4% in ≥60Gy group and 29.2%, 
7.5% in <60Gy group (p<0.001). Multivariate factor analysis 
revealed that combining visceral metastases, combining 
mediastinal failure, salvage radiotherapy, salvage radiation 
dose and salvage treatment model may be considered 
favourable prognostic factors. 
 
Conclusion: Salvage radiotherapy may improve survival of 
patients with supraclavicular lymph node metastases after 
esophagectomy. Combined radiochemotherapy and no 
combining visceral metastases and a salvage radiation dose 
≥60 Gy were associated with a better prognosis for those 
patients. 
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Purpose or Objective: To evaluate the correlation between 
radiation dose and locoregional control (LRC) for patients 
with stage II-III esophageal cancer treated with definitive 
concurrent chemo-radiotherapy (CCRT). 
 
Material and Methods: The medical records of 236 patients 
with clinical stage II and III esophageal cancer treated with 
definitive CCRT at the Yonsei Cancer Center between Feb 
1994 and May 2013 were retrospectively reviewed. Among 
these patients, 120 received a radiation dose of < 60 Gy 
(standard-dose group), while 116 received a radiation dose of 
≥ 60 Gy (high-dose group). The median dose of radiation in 
the standard and high dose groups was 50.4 Gy (range, 45.0-
59.4 Gy) and 63 Gy (range, 60.0-66.6 Gy). Concurrent 5-
FU/cisplatin (FP) chemotherapy (CHT) was performed in 82.2 
% of patients. 
 
Results: The patient characteristics had no differences in 
age, sex, pathology, grade, tumor length, and clinical stage 
between the two groups. Patients with high Karnofsky 
performance status scale and lower thoracic esophageal 
tumor were included more in standard dose group (p = 0.017 
and 0.038). Maintenance CHT was performed more in 
standard dose group (45% versus 30.2%, p = 0.037) and FP 
CHT was more frequently used in high dose group (76.7% vs. 
87.9%, p = 0.019). The median follow-up time for all patients 
was 19.2 months (range, 2.2-164.7). Of all patients, 2-yr and 
5-yr LRC rate were 60.0% and 48.4%. The median progression-
free survival (PFS) and overall survival (OS) were 13.2 months 
and 26.2 months, respectively. Patients in the high-dose 
group had a significantly better LRC (2-yr LRC rate, 50.3% vs. 
69.1%, p = 0.002), PFS (median, 11.7 vs. 16.7 months, p = 
0.029) and OS (median, 22.3 vs. 35.1 months, p = 0.043). The 
complete clinical response (CR) rate was significantly higher 
in the high-dose group (44.2% vs. 62.1%, p = 0.007). The 
treatment-related toxicities did not show a significant 
difference between the both groups (p = 0.936), although it 
was difficult to assess due to a retrospective fashion. On 
multivariate analysis, sex (female), radiation dose (≥ 60 Gy) 
and use of maintenance CHT were independent predictors for 
improved LRC, and sex (female), clinical stage (stage II vs. 
III), radiation dose (≥ 60 Gy) and use of maintenance CHT 
were significant predictive factors for OS. 
 
Conclusion: A higher radiation dose of > 60 Gy is associated 
with increased LRC, PFS and OS for patients with stage II-III 
esophageal cancer treated with definitive CCRT. 
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